General Information
Drug ID
DR00119
Drug Name
Arsenic trioxide
Synonyms
Acide arsenieux [French]; Anhydride arsenieux [French]; Arseni trioxydum; Arsenic blanc [French]; Arsenic oxide (As2O3); Arsenic trioxide (JP15/USAN); Arsenic trioxide [JAN]; Arsenic trioxide [UN1561] [Poison]; Arsenic(3+); Arsenic(III) trioxide; Arsenigen saure [German]; Arsenious Acid Anhydride; Arsenious trioxide; Arsenous oxide [ISO]; Arsenox; Arsentrioxide; Naonobin; Oxyde Arsenieux; Oxyde Arsenieux [ISO-French]; Oxygen(2-); Trisenox; Trisenox (TN); Trixenox
Drug Type
Small molecular drug
Indication Acute lymphoblastic leukemia [ICD11: 2B33.0] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=14888"></iframe>
3D MOL 2D MOL
Formula
As2O3
Canonical SMILES
[O-2].[O-2].[O-2].[As+3].[As+3]
InChI
InChI=1S/2As.3O/q2*+3;3*-2
InChIKey
QTLQKAJBUDWPIB-UHFFFAOYSA-N
CAS Number
CAS 1327-53-3
Pharmaceutical Properties Molecular Weight 197.84 Topological Polar Surface Area 3
Heavy Atom Count 5 Rotatable Bond Count 0
Hydrogen Bond Donor Count 0 Hydrogen Bond Acceptor Count 3
PubChem CID
14888
PubChem SID
104335670 , 126409444 , 126691141 , 134981320 , 164806579 , 180680593 , 184609025 , 252559753 , 29282900 , 49854936 , 57328779 , 77866200 , 853981
ChEBI ID
ChEBI:30621
TTD Drug ID
D07VIK
DT(s) Transporting This Drug MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [2]
P-GP Transporter Info P-glycoprotein 1 Substrate [3]
References
1 Arsenic trioxide was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 MRP2 and acquired tolerance to inorganic arsenic in the kidney of killifish (Fundulus heteroclitus). Toxicol Sci. 2007 May;97(1):103-10.
3 Arsenic trioxide induces apoptosis equally in T lymphoblastoid leukemia MOLT-4 cells and P-gp-expressing daunorubicin-resistant MOLT-4 cells. Cancer Chemother Pharmacol. 2003 Feb;51(2):119-26.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.